Isidakamizwa se-HIV sithuthelelwe ekukhethweni okukhethwa kuqala ku-US
I-Tivicay (i-dolutegravir) iyi- integrase-inhibitor ye- anti- antiretroviral esetshenziswa ekwelapheni kwe-HIV. Kwakuyesibili eklasini ye-integrase inhibitors ezovunyelwa yi-US Food and Drug Administration (FDA).
I-Tivicay yanikezwa ilayisense ye-FDA ngo-Agasti 12, 2013, ukuze isetshenziswe kubantu abadala kanye nabantwana abaneminyaka engu-12 noma ngaphezulu abala ubunzima obungama-88 lbs (40kg) futhi abazange baphathwe ngaphambilini nge-integrase inhibitor.
(I-Tivicay ayitholakali okwamanje ezinganeni ezingaphansi kweminyaka engu-12 nakuba izivivinyo zesigaba se-Phase III ziyaqhubeka ukuhlola ukuphepha nokusebenza kwayo kulelo qembu lobudala.)
I-Tivicay iyingxenye ye-once-daily, fixed-dose combination combination, Triumeq , ehlanganisa izidakamizwa abacavir ne lamivudine. I-Triumeq yamukelwa yi-FDA ngo-Agasti 22, 2014.
Amaphuzu avelele wezokwelapha
Ucwaningo lwe-VIKING-3 lubonise ukuthi iTivicay yayiphumelele kuma-63% weziguli ezikhulile eziphikisana namakilasi amaningi e-HIV, kuhlanganise ne-integrase inhibitors i-Isentress (ratelgravir) ne-elvitegravir (etholakala kuphilisi elilodwa, i-dose fixed-dose combination drug, Stribild ) .
Ucwaningo lwe-SINGLE lwembula ukuthi iziguli zaseTivicay zinezimo eziphansi zokuyeka ngenxa yemiphumela emibi yezidakamizwa kune- Atripla (tenofovir + emtricitabine + efavirenz). Ngemuva kwamaviki angu-48, izibalo ezingu-2% ezifundweni ezisekelwe eTivicay zisekelwe ukwelapha ngokubhekiselele ku-10% kulabo abathola i-Atripla.
Isilinganiso
- Abantu abadala: 50mg tablet, kanye nsuku zonke
- Abantu abadala abanomshini othize we-integrase-inhibitor: 50mg tablet, kabili ngosuku
- Izingane ezingu-12 nangaphezulu (ezilinganisa 88 lbs / 40kg noma ngaphezulu): i-tablet 50mg, kanye ngosuku
Ukwengeza, izingane ezilawulwa u- Sustiva (efavirenz), i-Aptivus (tipranavir) + ne-Norvir (ritonavir), i-Lexiva (fosamprenavir) + ne-Norvir (ritonavir), noma i-rifampin, umthamo we-Tivicay u-50mg, kabili ngosuku.
Akukaziwa ukuthi i-Tivicay iphumelele yini kubantwana abane-integrase-inhibitor-ehambisana nokumelana.
Ukulawulwa kwezidakamizwa
I-Tivicay ingathathwa noma ngaphandle kokudla, futhi nganoma isiphi isikhathi sosuku.
Imiphumela Ejwayelekile Ejwayelekile
Imiphumela emibi kakhulu eyaziwayo (eyenzeka ngo-2% noma ngaphansi kwamacala) yi:
- Ukungalali
- Izinwele
- Isizungu
- I-nausea
Ukusebenzisana kwezidakamizwa noma ukungahambisani
I-Tikosyn (i-dofetilidedi), esetshenziselwa ukwelashwa kwe-arrhythmia (ukushaya kwenhliziyo okungavamile), iyaphikisana nokusetshenziswa ne-Tivicay.
Ukuze ugweme ukusebenzisana kwezidakamizwa-izidakamizwa, welule udokotela wakho ukuthi uthatha noma yimiphi imithi elandelayo noma izithako ezilandelayo:
- Imithi ye-antiretroviral: Sustiva (efavirenz), Intelence (etravirine), i-Viramun (i-nevirapine), kanye nokuhlanganiswa kweLexiva (fosamprenavir) + Norvir (ritonavir), noma i-Aptivus (tipranavir) + ne-Norvir (ritonavir)
- Imithi yokwelashwa: i-Trileptal (oxcarbazepine), i-Dilantin (phenytoin), iPhenytek (phenytoin), i-Luminal (phenobarbital), noma izidakamizwa ezisuselwa ku-carbamazepine njengeCarrol, Equetro, Tegretol, Teril, noma i-Epitol
- Ama-antibiotics ase-Rifampin: Rifadan, Rifater, Rifamate, Rimactane
- Imithi ehambisana nesifo sikashukela i-Metformin: Fortamet, Glucophage, Glumetza, Riomet
- Wort St. John's Wort
Ukucabangela
- Iziguli ezithola impendulo yokugula ngemuva kokuqala i-Tivicay kufanele zithinte udokotela wazo ngokushesha . Ukwelapha kumele kumiswe futhi ukwelashwa kufuneke uma ukuqhuma kuhambisane nomkhuhlane, izinhlungu noma izinhlungu ezihlangene, izilonda noma izilonda, ubomvu noma ukuvuvukala kwamehlo, ukuvuvukala ubuso noma umlomo, noma izinkinga zokuphefumula. Iziguli eziye zabhekana nokusabela okuthinta i-Tivicay akufanele ziphinde zinselele nezidakamizwa ngemuva kokuxazulula izimpawu.
- I-Tivicay kufanele ithathwe amahora amabili ngaphambi kokuqala noma amahora ayisithupha ngemuva kokuthatha ama-antacids noma ama-laxatives ane-aluminium- noma ama-magnesium, ama-supplements, ama-calcium supplements, imithi ephucuziwe, noma i-Carafate (sucralfate) esebenzisa ukwelashwa kwezilonda ze-duodenal.
- Yazisa udokotela wakho nganoma yisiphi isimo sesibindi ongaba nayo ngaphambi kokuqala i-Tivicay. Kungase kube khona ingozi yokwanda kwesibindi kwabanye, ikakhulukazi kubantu abane-hepatitis B (HVB), i- hepatitis C (HCV) , noma ukukhubazeka kwesibindi esandulele. Ama-enzyme ye-fover kufanele ahlolwe njalo njengengxenye yokuhlolwa kwegazi lomuntu ukuthatha i-Tivicay.
> Imithombo:
Ilabhulali Kazwelonke Yezokwelapha yase-US. Ithebhulethi ye-TIVICAY (i-dolutegravir sodium), ifilimu iboshwe. " I-Bethesda, e-Maryland; ibuyekezwe ngo-Agasti 2013.
ViiV Healthcare. "I-ViiV Healthcare ithola imvume ye-FDA ye-Triumeq." ILondon, eNgilandi; ukukhishwa kwezindaba kukhishwe ngomhla ka-22 Agasti 2014.
Walmsley S .; I-Antela, A .; I-Clumeck, N .; et al. "I-Dolutegravir (i-DTG; S / GSK1349572) + abacavir / lamivudine kanye ngezibalo nsuku zonke ziphakeme ngaphezu kwe-tenofovir / emtricitabine / efavirenz: imiphumela yamaviki angu-48 - SINGLE (ING114467)." I-52nd Interscience Conference mayelana nama-Antimicrobial Agents kanye ne-Chemotherapy. I-San Francisco; September 9-12, 2012; Abstract H-556b.
I-Nichols, G .; Grossberg, R .; I-Lazzarin, A .; et al. "Umsebenzi we-Antiviral we- Dolutegravir ezifundweni ezihlulekayo kwi-Reggraen-based Based Regimen: Iviki 24 Imiphumela yeSigaba sesi-3 kusuka ku-VIKING-3." I-Congress ye-11 ye-International Congress on Therapy Therapy in HIV Infection (i-HIV11). I-Glasgow, eScotland; NgoNovemba 11-15, 2012; Abstract O232.